Yoğun Bakımda Antibiyotik Kullanımı

Çağatay AA, Özsüt H. Yoğun Bakım Ünitesi İnfeksiyonları ve Antimikrobik Tedavi. Yoğun Bakım Dergisi, 1 (1): 21. 2001;32.

Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clinical infectious diseases. 2006;43(Supplement_2):S82-S8.

Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Annals of internal medicine. 2001;134(4):298-314.

Duszyńska W. Pharmacokinetic-pharmacodynamic modelling of antibiotic therapy in severe sepsis. Anaesthesiology intensive therapy. 2012;44(3):158-64.

Bongard FS, Sue DY. Current critical care diagnosis and treatment, 2. Edition, Lange medical books/McGrawHill. 2002:391-434.

Shoemaker WC, Ayres SM, Grenvik AKE, Holbrook PR. Textbook of critical care, 4. Edition, W.B. Saunders company.2000:p.659-74.

Tomasz A. Multiple-Antibiotic-Resistant Pathogenic Bacteria--A Report on the Rockefeller University Workshop. New England journal of medicine. 1994;330(17):1247-51.

Segal-Maurer S, Urban C, Rahal Jr JJ. Current perspectives on multidrug-resistant bacteria: epidemiology and control. Infectious disease clinics of North America. 1996 Dec 1;10(4):939-57.

Wright AJ, Wilkowske CJ. The penicillins. Mayo Clinic proceedings. 1991;66(10):1047-63.

Akalın H. Klinik uygulamada antibiyotikler ve diğer antimikrobiyal ilaçlar, Güneş Kitapevi, 1. Basım. 1994:197-217.

Gorbach SL, Mensa J, Gatell JM. 1997 pocket book of antimicrobial therapy and prevention: Williams & Wilkins.; 1997.

Mandel GL, Bennett JE, Dolin R. Principles end practice of infectious diseases, 4th ed., Churchill Livingstone. 1995:279-305.

Cunha BA. The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. The Medical clinics of North America. 1995;79(3):581-97.

Jacoby GA, Munoz-Price LS. The new beta-lactamases. The New England journal of medicine. 2005;352(4):380-91.

Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Current opinion in pharmacology. 2012;12(5):527-34.

Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatric outpatients. Archives of disease in childhood. 2011;96(6):590-5.

Resistance A. Implication for Global Health and Novel Intervention Strategies: Workshop Summary, Institute of Medicine (US), Forum on Microbial Threats. Washington (DC): National Academies Press (US); 2010.

Hellinger WC, Brewer NS, editors. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clinic proceedings; 1999: Elsevier.

Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously III infected patients receiving antibiotics: experience with imipenem/cilastatin. The American journal of medicine. 1988;84(5):911-8.

Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. Journal of Antimicrobial Chemotherapy. 1995;35(1):75-84.

Hellinger WC, Brewer NS. Imipenem. Mayo Clinic proceedings. 1991;66(10):1074-81.

Pitkin DH, Sheikh W, Nadler HL. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Clinical infectious diseases. 1997;24(Supplement_2):S238-S48.

Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clinical Infectious Diseases. 2008;47(Supplement_1):S32-S40.

Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell KL. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrobial agents and chemotherapy. 2000;44(9):2389-94.

Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrobial agents and chemotherapy. 2001;45(6):1915-8.

Gill CJ, Jackson JJ, Gerckens LS, Pelak BA, Thompson RK, Sundelof JG, et al. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrobial agents and chemotherapy. 1998;42(8):1996-2001.

Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of Ertapenem (MK-0826) versusEnterobacteriaceae with Potent β-Lactamases. Antimicrobial agents and chemotherapy. 2001;45(10):2831-7.

Sundelof J, Hajdu R, Gill C, Thompson R, Rosen H, Kropp H. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrobial agents and chemotherapy. 1997;41(8):1743-8.

Sader HS, Gales AC. Emerging strategies in infectious diseases. Drugs. 2001;61(5):553-64.

Akalın HE. Antibiyotikler, Özyurt matbaası,1. baskı. 1989:73-8.

Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases, Fourth edition, Curhchill Livingstone.1995:264-72.

Saxon A, Hassner A, Swabb EA, Wheeler B, Adkinson Jr NF. Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. Journal of Infectious Diseases. 1984;149(1):16-22.

SARUBBI FA, HULL JH. Amikacin serum concentrations: prediction of levels and dosage guidelines. Annals of internal medicine. 1978;89(5_Part_1):612-8.

Pancoast SJ. Aminoglycoside antibiotics in clinical use. Medical Clinics of North America. 1988;72(3):581-612.

EDSON RS, TERRELL CL, editors. The aminoglycosides. Mayo Clinic proceedings; 1991: Elsevier.

Leblebicioğlu H, Usluer G, Ulusoy S. Güncel Bilgiler Işığı Altında Antibiyotikler, Bilimsel Tıp Yayınları. 2003:313-24.

Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones. Drugs. 2002;62(1):13-59.

Van Bambeke F, Michot J, Van Eldere J, Tulkens P. Erratum: Quinolones in 2005: An update (Clinical Microbiology and Infection (2005) vol. 11 (256-280)). Clinical Microbiology and Infection. 2005;11(6):513.

Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1987;31(6):860-4.

Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Current opinion in pharmacology. 2004;4(5):471-8.

Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. Jama. 1993;269(1):71-5.

Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Antihistamine prophylaxis permits rapid vancomycin infusion. Critical care medicine. 1999;27(9):1732-7.

Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infectious disease clinics of North America. 2009;23(4):965-82, ix.

Bergeron L, Boulé M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Annals of Pharmacotherapy. 2005;39(5):956-61.

Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am. 2009;23(4):965-82, ix.

American Society of Health-System P. AHFS drug information 2012. 2012. Bethesda: American Society of Hospital Pharmacists. 2012;454-7.

Molavi A, LeFrock JL, Prince RA. Metronidazole. Medical Clinics of North America. 1982;66(1):121-33.

Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. New England Journal of Medicine. 1996;334(4):240-6.

Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. American journal of respiratory and critical care medicine. 2011;183(1):96-128.

Carlson MA, Condon RE. Nephrotoxicity of amphotericin B. Journal of the American College of Surgeons. 1994;179(3):361-81.

Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infectious disease clinics of North America. 2003;17(1):159-91, ix.

Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: 2-Volume Set. Elsevier Health Sciences; 2014 Aug 28.